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Abstract The study is a part of the European Community Respiratory Health Survey. A random sample (n=351) of
20--44-year olds and persons of the same agewith asthma-like symptoms or current asthmamedication according to a
postal questionnaire (n=95) were studied. Interview was taken, methacholine challenge was done and ECP, total and
specific IgE were measured from serum.The median S-ECP value was 8.0 mg/l in the random sample.The geometric
mean of S-ECP was higher in subjectswith, thanwithout atopy (10.2. vs 8.9 mg/l, Po0.01) and in subjects with bronchial
hyperresponsiveness (BHR) thanin subjectswithout BHR (9.9 vs 8.0 mg/l,Po0.01).The levels correlatedweakly to forced
expiratory volume in one second (FEV1) (r=0.13, Po0.01) andwere not independentlycorrelatedwith respiratory symp-
toms, asthma or FEV1after adjusting for BHR,IgE, sensitisation and smoking.Ourresults indicate thatthe level of eosino-
phil activation is low in a populationwith a lowprevalence of atopy, evenwhen BHR is common.r 2002 Published by Elsevier
Science Ltd
doi:10.1053/rmed.2002.1320, available online athttp://www.idealibrary.comon
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In the last two decades, the conception of asthma has
changed from regarding it as a disease of the bronchial
muscles to an in£ammatory airwaydisease (1). Epidemio-
logical asthma research has, however, usuallybeenbased
on questionnaires and lung function data, whilemethods
for assessing airway in£ammationhave onlybeenused to
a limited degree (2).
The number of eosinophil granulocytes in peripheral
blood (B-Eos) is traditionally themost commonmethod
for assessing in£ammation in epidemiological research
(3--7).More recently,measurements of eosinophil degra-
nulation products, such as eosinophil cationic protein
(ECP) inperipheralbloodhasbeen introducedas ameth-
od to assess and monitor in£ammation in asthmatic pa-
tients (8--10).There is, however, limited experience from
epidemiological research and that only from Scandinavia
(11,12).Received 26 July 2001, accepted in revised form15 January 2002.
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+372 7449920; E-mail: rain.jogi@kliinikum.eeFurthermore, di⁄culties in de¢ning asthma in epide-
miological studies have enforced to ¢nd objective mea-
sures with relative stability over time. Bronchial
hyperresponsiveness (BHR) has mostly been used as an
objective marker of asthma in epidemiological studies.
Generally, theprevalence of BHRparallels that of self-re-
ported asthma and wheeze (13,14). Previous analyses of
population samples in Estonia have, however, led to con-
tradictory results in low prevalence of self-reported
asthma and atopy contrasting to high prevalence of
BHR and respiratory symptoms including wheeze both
in children (15,16) and in adults (17,18).These results could
re£ecteither low awarenesswith concurrenthighpreva-
lence of nonatopic asthma or high prevalence of other
respiratory conditions resulting in high prevalence of
BHR in this region. In this context, high S-ECP levels in
the population would support the ¢rst and low levels
the latter hypothesis.
The aim of this investigation was to describe the dis-
tribution of S-ECP in a population with a low prevalence
of atopy and allergic respiratory disorders and to study
the relationship between levels of S-ECP and variables
related to asthma and allergy.
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Study areas and subjects
The subjects were enrolled as part of the European
Community Respiratory Health Survey (ECRHS)(19). In
the ¢rst phase of the study, a questionnaire including se-
ven questions on asthma-related symptoms was mailed
to 3000 individuals between 20 and 44 years of age, with
equal number from either sex(20).The study population
was randomly selected from the Civil Register.To avoid
linguistic problems, only people of Estonian nationality
were selected.From this cohort, a further random sam-
ple of 800 persons was selected to the clinical phase of
the study. Only individuals who had answered to the
mailed questionnaire were invited to participate
(n=723). In order to enrich the samplewith symptomatic
individuals, all persons from the original studygroupwho
reported use of asthma medication, attacks of asthma,
or awakening because of shortness of breath and who
werenot already included in the random samplewere in-
vited to participate (n=197).
Questionnaire
The ECRHS questionnaire was used both for screening
and interview (19--21). The questionnaires were trans-
lated fromEnglish into Estonian and thenback-translated
into English by an independent person.The interview in-
cluded questions on symptoms, diagnoses, smoking his-
tory, parental smoking history, family structure, family
history, early environment, education, employment,
home environment, diet, use of medicines, attitudes to
medicines and the use of health services.
S-ECP
The blood samples that were collected for ECP mea-
surements were kept at 241C for 60min before they
were centrifuged. Sera were stored at 201C.The con-
centration of S-ECP was assayedwith a double antibody
radioimmunoassay (Pharmacia Diagnostics, Uppsala,
Sweden).
Serum IgE levels and circulating IgE
antibodies
Serum IgE levels and IgE antibodies against D. pteronyssi-
nus, timothy, birch, cat and Cladosporium were deter-
mined by Pharmacia CAPt system (Pharmacia
Diagnostics,Uppsala, Sweden).
Spirometry andmethacholine challenge
Forced expiratory volume in one second (FEV1) was
measuredwith JLeger Flowscreen (Erich JMEGERGmbH&CoKG,Wˇrzburg,Germany).The predicted valuewas
calculated for each subject(22). In this analysis, FEV1was
expressed as a percentage of thepredictedvalue.Metha-
choline challengewas carriedoutusing a dosimeter Spira
Elektro 2 (Respiratory Care Centre, HLmeenlinna, Fin-
land). The results were expressed as slope using the
method described by Chinn et al. (13). In addition, sub-
jects with a fall of FEV1by at least 20% with an accumu-
lated methacholine dose of 2mg was categorised as
BHR.
De¢nitions
Atopy was de¢ned as the presence of serum IgE antibo-
dies0.35kU/l against at least one allergen.
Wheezewas de¢ned as answering ‘‘yes’’ to the follow-
ing question: ‘‘Have you had wheezing or whistling in
your chest at any time in the last12 months?’’
Asthma was de¢ned as an a⁄rmative answer to the
question: ‘‘Have you ever had asthma?’’
Allergic rhinitis was de¢ned as a positive answer to
the question: ‘‘Do you have any nasal allergies, including
hay fever?’’
Skin allergy was de¢ned as answering ‘‘yes’’ to the
question: ‘‘Have you ever had eczema or any kind of skin
allergy?’’
Ethical considerations
All participants gave their informed consent. The study
was approved by the Ethics Committee of Tartu Univer-
sity.
Statistical analysis
The statistical analysiswas performedwith the StatView
5 software package (SAS Institute Inc,Cary,NC,U.S.A.).
Chi-square- and t-tests were used to analyse di¡erences
between groups.Linear regressionwas used to correlate
two continuous variables and logistic andmultiple linear
regression for multiple variables. Log-transformation
was performed to achieve a normal distribution of S-
ECP and S-IgE. S-ECP values are presented as geometric
mean (7SD). A P-value o0.05 was regarded as statisti-
cally signi¢cant.
RESULTS
S-ECP was obtained from 351subjects from the random
sample and 95 subjects from the enriched sample. The
characteristics of subjects from the random sample is
presented inTable 1.When the symptomatic sample was
also included the prevalence of atopy, BHR and asthma
increased to 22, 22 and 4%, respectively.
TABLE 1. Characteristics of the random population (%)
andmean (range) in the clinical phase of ECRHS inTartu,
Estonia
Randompopulation
(n=351)
Women 55.7
Age 32 (21--45)
Current smokers 35.0
Atopy 19.1
BHR 18.6
Self-reported asthma 2.0
Nasal allergy 16.7
Skin allergy 45.6
Wheeze 21.8
FEV1 (% predicted) 108 (58--157)
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FIG. 1. Distribution of S-ECP levels in a random population
sample of 20--44 yearolds inTartu,Estonia.
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postal questionnaire was higher among persons subject
to S-ECP measurements than among those who did not
participate in the clinical phase of the study (19 vs 10%;
Po0.01). Respiratory symptoms associated with wheez-
ing andnightcoughwere alsomoreprevalent amongpar-
ticipants in the second phase of the study.
The S-ECP levels in the random population sample
were clearly skewed, with a median value of 8.0mg/l and
an interquartile range of 6.0 --12.0mg/l (Fig. 1). The levels
were not signi¢cantly related to gender or age but they
were signi¢cantly higher in current smokers than in non-
smokers (9.0 (4.8 --16.9) vs 7.9 (4.6 --13.6) mg/l, Po0.05).
Further, the S-ECP levels were signi¢cantly higher in
atopic than in non-atopic subjects (10.2 (5.8 --17.0) vs 8.2
(4.6 --14.9) mg/l, Po0.01) and higher in subjects with, than
withoutBHR (9.9 (5.6 --17.4) vs 8.0 (4.5--14.3)mg/l,Po0.01).
S-ECP also correlated weakly with the IgE levels (r=0.19,
Po0.001) and with bronchial responsiveness (r=0.11,Po0.05). Furthermore, the S-ECP levels were higher in
subjectswith self-reported asthma than in subjectswith-
out asthma and inwheezing as compared to non-wheez-
ing subjects (10.6 (6.2--18.2) vs 8.0 (4.4--14.4) mg/l,
Po0.001), while there was no relationship between S-
ECP and either nasal or skin allergy (Fig. 2).
The speci¢city and sensitivity of an S-ECP value above
the interquartile range (12.0mg/l) for atopy were 32 and
80%, respectively, for BHR 30 and 80%, for self-reported
asthma 63 and 97% and for wheeze 36 and 76%.
Logistic regression analysis revealed that wheeze was
independently related to atopy, BHR and current smok-
ing, while asthma was independently related to atopy.
No independent signi¢cant correlation was found be-
tween S-ECP above the 75% interquartile range (12.0m
g/l) andwheeze or asthma (Table 2).Expressing S-ECP as
a continuous variable did not change the result of the
analysis.
Although S-ECPwas signi¢cantlyrelated to FEV1in lin-
ear regression (r=0.13, Po0.01), this correlation did not
remain signi¢cant after adjusting for age, gender, smok-
ing, total IgE and bronchial responsiveness (partial r-va-
lue =0.05, P=0.32).
DISCUSSION
Themain ¢nding in this population study is that although
S-ECP correlated to self-reported asthma, atopy, BHR,
asthma symptoms and lung function, it had no indepen-
dent predictive value when other asthma-related vari-
ables were taken into account.
Tobacco smoking was associatedwith elevated S-ECP
levelswhich concords to a previous study (23). Epidemio-
logical studies indicate that high blood eosinophil counts
may be independently related to the decline in FEV1
(7,24).We were unable to con¢rm any independent rela-
tionship between FEV1and S-ECP.
Theresults correspondwith those of a previous Swed-
ish study using an identical protocol. The S-ECP levels
were, however, considerably lower in Tartu than those
in Sweden (11).The median S-ECP level in Uppsala, Swe-
den was 11.9mg/l compared to 8.0mg/l inTartu. Although
the analyseswere done in di¡erent laboratories, the pro-
tocol for S-ECP measurements was identical in the two
studies.We cannot entirely exclude technical di¡erences
since in Swedish study the blood was allowed to coagu-
late at room temperature before centrifugation. This
would, however, not change our results of lower levels
of S-ECP inTartu, as the level of ECP riseswith increasing
temperatures and the room temperature is generally
lower than 241C, thus diminishing the di¡erence that
we revealed (25). It is therefore more likely that the re-
sults re£ect a di¡erence in eosinophil activationbetween
these two populations.
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FIG. 2. Levels of S-ECP in subjects with and without self-reported asthma, nasal allergy and skin allergy.The box plots show the
values ofmedian, interquartile range and the10th (>) and the 90th percentiles (T).
TABLE 2. Independent relationships between asthma
symptoms, S-ECP, atopy, BHR and smoking, as adjusted
for age andgender (OR and 95% CI).
Wheeze Asthma
S-ECPabove12 mg/l 1.4 (0.7--2.7) 2.4 (0.5--11)
Atopy 3.8 (1.9--7.3) 8.6 (1.8--41)
BHR 2.5 (1.3--5.0) 3.9 (0.9--18)
Current smoking 3.5 (1.9--6.6) 0.5 (0.1--2.3)
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of asthma abates the possibility to estimate the value of
any certain parameter inmeasuring asthma in epidemio-
logical studies. Furthermore, atopy, elevated S-ECP and
BHRmaybe on causal pathway to asthma: atopic sensiti-
sation being the prerequisite to allergic in£ammation,
the latter marked by elevated S-ECP. Activation of eosi-
nophils in its turn canresult in increased BHR. It is there-
fore not surprising that after controlling for the e¡ect of
atopy andBHR, S-ECPno longer remains associatedwith
asthma symptoms and self-reported asthma. Thus, in-
£ammatory markers such as S-ECP, despite not having
independent predictive value for asthma, can be useful
in international asthma surveys, particularly, when com-
paring populations with large di¡erences in the preva-
lence of respiratory diseases other than asthma which
are associatedwith BHR.Determination of S-ECP levels
may alsobeusefulwhencomparingpopulationswithhigh
and low awareness of asthma. Previous analyses of the
study group has revealed high prevalence of BHR (18)
and respiratory symptoms, including wheeze (20), while
the prevalence of atopy, diagnosed asthma and asthma
treatmentwere low as compared to other centresparti-
cipating in ECRHS (17,20,21). The corresponding preva-
lence of atopy in Uppsala, Sweden was 32.3% (21) and
Tartu had the second lowest prevalence of atopy amongall the centres in the ECRHS (26).The low prevalence of
eosinophil activation would support our previous sug-
gestions that the prevalence of asthma is low in Estonia
(20,21).
We conclude that in this Estonian population sample
S-ECP was elevated in subjects with either atopy or
BHR, but the levels were not relatedwith asthma symp-
toms or lung function when other asthma-related vari-
ables were controlled for. Our results indicate that the
level of eosinophil activation is low in a population with
a low prevalence of atopy, evenwhen bronchial hyperre-
sponsiveness is common.
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